iHateHospitals.com

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]

(Mesothelioma News) ROCKVILLE, Md. — Human Genome Sciences, Inc. today announced that it has completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (mapatumumab) in combination with the chemotherapy (serious, serious drugs) agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). “There is [...]

(Mesothelioma News) BOTHELL, WA and VANCOUVER — OncoGenex Pharmaceuticals announced today that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer. OGX-011 is currently completing five Phase 2 clinical studies in prostate, lung and breast cancer, and [...]

DRUGS & RX: Studies demonstrate efficacy and safety of VisonacTM and the potential for a simplified Photodynamic Therapy (PDT) procedure for treatment of moderate to severe acne
Oslo, Norway, August 27, 2008 - Photocure announces positive preliminary results…

View the source of this article…

Photocure Announces Positive Phase II Results with Visonac for Acne was another wonderful and [...]

DRUGS & RX: LONDON, 27 August 2008: Ark Therapeutics Group plc (“Ark” or the “Company”) today nnounces that enrolment of patients into its Phase III pilot study for VitorTM (Study 208) has commenced. VitorTM is Ark’s product to…

View the source of this article…

Ark’s Vitor commences patient enrolment into Phase III pilot study was another wonderful [...]

DRUGS & RX: PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–Aug 26, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new Phase II data…

View the source of this article…

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program [...]

DRUGS & RX: KNOXVILLE, Tenn.–(BUSINESS WIRE)–Aug 26, 2008 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the Lead Investigator for its phase 2 melanoma study,…

View the source of this article…

Professor John F. Thompson to Present at Perspectives in Melanoma XII, Thursday October 2, 2008 was another [...]

DRUGS & RX: PARSIPPANY, N.J.–(BUSINESS WIRE)–Aug. 26, 2008 - The Medicines Company (NASDAQ: MDCO) today announced that the results of VELOCITY, a pivotal Phase 3 safety and efficacy trial of its new intravenous (IV) therapy Cleviprex(TM) (clevidipine…

View the source of this article…

New Publication Shows Cleviprex is Safe and Effective for Treatment of Acute, Severe Hypertension [...]

DRUGS & RX: SEATTLE, August 26, 2008 /PRNewswire/ — Omeros Corporation today announced the publication of the results from a Phase 1/Phase 2 trial investigating OMS103HP in arthroscopic anterior cruciate ligament (ACL) reconstruction surgery. OMS103HP is an…

View the source of this article…

Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic [...]

DRUGS & RX: VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness
ROCKVILLE, Md., Aug. 26, 2008 /PRNewswire-FirstCall/ — Novavax, Inc. announced today favorable results from the second stage of…

View the source of this article…

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program was another wonderful [...]

DRUGS & RX: STOCKHOLM, SWEDEN, August 26, 2008 - Pharmalink AB today announces positive results from a follow-on Phase III study of Xepol, its candidate for the treatment of post-polio syndrome (PPS). The data have shown the candidate to be effective and…

View the source of this article…

Pharmalink Reports Positive Phase III Results for Xepol, a [...]